RT Journal Article
SR Electronic
T1 <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 410
OP 414
DO 10.2967/jnumed.121.262240
VO 63
IS 3
A1 Oliver Sartor
A1 Christian la Fougère
A1 Markus Essler
A1 Samer Ezziddin
A1 Gero Kramer
A1 Jörg Ellinger
A1 Luke Nordquist
A1 John Sylvester
A1 Giovanni Paganelli
A1 Avivit Peer
A1 Martin Bögemann
A1 Jeffrey Meltzer
A1 Per Sandström
A1 Frank Verholen
A1 Daniel Y. Song
YR 2022
UL http://jnm.snmjournals.org/content/63/3/410.abstract
AB We analyzed real-world clinical outcomes of sequential α-/β-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received 177Lu-prostate-specific membrane antigen ligand (177Lu-PSMA) after 223Ra in the ongoing noninterventional REASSURE study (223Ra α-Emitter Agent in Nonintervention Safety Study in mCRPC Population for Long-Term Evaluation; NCT02141438). Results: Patients received 223Ra for a median of 6 injections and subsequent 177Lu-PSMA for a median of 3.5 mo (≥ the fourth therapy in 69%). The median time between 223Ra and 177Lu-PSMA treatment was 8 mo (range, 1–31 mo). Grade 3 hematologic events occurred in 9 of 26 patients (during or after 177Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 mo from the 223Ra start and 13.2 mo from the 177Lu-PSMA start. Conclusion: Although the small sample size precludes definitive conclusions, these preliminary data, especially the 177Lu-PSMA treatment duration, suggest that the use of 177Lu-PSMA after 223Ra is feasible in this real-world setting.